Pemvidutide record · updated 18h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only

All 5 studies Jump to the evidence Compare

What is Pemvidutide used for?

Research peptide discovered via AI researcher. research peptide

How it works: GLP-1/glucagon receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Pemvidutide sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Current
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 6 registered trials. It describes the research record, not a recommendation.

Identity

NamePemvidutide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelModerate Research

Discovered byThe Librarian · 2026

Pharmacology

MechanismGLP-1/glucagon receptor agonist

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence0.70

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 12, 2026. How this works →

Research stats

Total studies5

Human / animal / cellular2 / 0 / 0

Highest trial phasePhase 2

Years covered2025–2026

Latest study6d ago

Publication history

20252026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 5 Semantic Scholar UniProt

Study register

5 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. FindingMASH resolution without fibrosis worsening: 58% in 1.2 mg pemvidutide group, p<0.0001.	Human	2025	Full text read0.80
The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. TakeawayNot reported in abstract.	Human	2025	Title only0.10
Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. FindingNot reported in abstract.	review	2026	Full text read0.80
Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. Finding-52.90 MD liver fat content at 12 weeks, 95% CI -71.60 to -34.20, P < 0.00001	review	2026	Full text read0.80
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. FindingRR 3.32, 95% CI 2.28-4.84; I² = 20% for MASH resolution or histological improvement without worsening of fibrosis.	review	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Pemvidutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Pemvidutide is discussed should be drawn from it.